AKT1 and Miyoshi myopathy: Nevertheless, targeting signaling pathways activated in canine and human MM, such as Ras/MAPK and PI3K/AKT/mTOR, remains a viable option due to their frequent activation and vital role in supporting tumor growth (4, 22).